The best time to take dacomitinib/dacomitinib

Dacomitinib/Dacomitinib (Dacomitinib) is an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), mainly used to treat non-small cell lung cancer. Regarding the optimal time to take dacomitinib, it really depends on a variety of factors, including the patient's specific situation, doctor's recommendations, and drug-food interactions.

There is no fixed standard for the taking time of dacomitinib. The mean absolute bioavailability of dacomitinib after oral administration is 80%. After a single oral dose of dacomitinib 45 mg in cancer patients, the median time to maximum concentration (Tmax) was approximately 6.0 hours (range, 2.0 to 24 hours). This means that each patient may take this medication at different times, depending on their specific situation and their doctor's recommendations. However, to ensure that the medication works best and to reduce possible side effects, patients should follow their doctor's instructions and try to take it at the same time every day.

Food may have a certain impact on the absorption and metabolism of dacomitinib. Taking some medicines with food may increase their absorption, while other medicines may be less absorbed by food. Administration of dacomitinib with a high-fat, high-calorie meal (approximately 800 to 1000 calories, of which 150, 250, and 500 to 600 calories from protein, carbohydrate, and fat, respectively) had no clinically meaningful effect on its pharmacokinetics. Dacomitinib can be taken on an empty stomach or with food. However, the specific method to choose needs to be determined based on the patient's individual situation and the doctor's advice.

In addition to the above factors, patients also need to be aware of the side effects of dacomitinib. This drug may cause some adverse reactions, such as nausea, vomiting, diarrhea, etc. If patients experience these symptoms, they should inform their doctor in time so that the dose of the drug can be adjusted or the time of taking the drug can be changed.